Johnson & Johnson - JNJ STOCK NEWS

Johnson & Johnson (NYSE: JNJ) released its 2020 Health for Humanity Report on June 9, 2021, detailing its environmental, social, and governance (ESG) performance. The report highlights progress towards the company's 2020 Goals, its response to COVID-19, and new 2025 Goals, emphasizing health equity and community support. Notable initiatives include a $50 million commitment to health workers and advancements in healthcare access. The report adheres to GRI Standards and includes SASB and TCFD disclosures, showcasing JNJ's dedication to transparency and sustainable value creation.

Johnson & Johnson (NYSE: JNJ) announced a collaboration with the WHO and the government of Sierra Leone to administer its Ebola vaccine regimen as part of an early access clinical program. This initiative aims to prevent further Ebola spread in West Africa, especially following a resurgence of cases in Guinea. The vaccine regimen has received WHO Prequalification, enhancing its accessibility in affected regions. The program targets health workers and vulnerable populations, with plans to vaccinate up to 200,000 individuals. Johnson & Johnson aims to bolster global health preparedness against infectious diseases.

Johnson & Johnson (JNJ) announced the resumption of its COVID-19 single-shot vaccine for adults in the U.S. under Emergency Use Authorization (EUA) following CDC and FDA approval. This decision comes after evaluating a rare blood clotting risk. The vaccine demonstrated 66.1% effectiveness against moderate to severe disease in the Phase 3 ENSEMBLE study. The company plans to file for a Biologics License Application later in 2021. Health authorities continue to monitor safety, emphasizing the need for prompt medical attention for specific symptoms. Updated EUA fact sheets are now available.

Johnson & Johnson (NYSE: JNJ) announced on April 20, 2021, that the European Medicines Agency's Pharmacovigilance Risk Assessment Committee confirmed the positive benefit-risk profile of its COVID-19 vaccine. Following the review of rare adverse events, the company will update vaccine information to include guidance on diagnosing and managing these cases. Shipments of the Janssen COVID-19 vaccine will resume in the EU, Norway, and Iceland. The vaccine demonstrated 85% effectiveness in preventing severe disease during the ENSEMBLE Phase 3 trial, with continued monitoring by health authorities.

Johnson & Johnson (NYSE: JNJ) reported strong first-quarter 2021 results, with reported sales reaching $22.32 billion, representing a 7.9% increase from $20.69 billion in 2020. Net earnings rose to $6.20 billion, up 6.9% year-over-year, resulting in an EPS of $2.32. The Pharmaceutical segment led growth with a 9.6% increase, driven by key products like DARZALEX and STELARA. Medical Devices also saw an 8.8% growth, aided by recovery from COVID impacts. However, Consumer Health segment sales declined 2.3% due to prior year comparisons.

Johnson & Johnson (NYSE: JNJ) has announced a 5.0% increase in its quarterly dividend, raising it from $1.01 to $1.06 per share. This marks the 59th consecutive year of dividend increases, reflecting the company's strong financial position and confidence in future growth. The annualized dividend is now $4.24 per share, up from $4.04. The next dividend is payable on June 8, 2021, to shareholders recorded by May 25, 2021, with an ex-dividend date of May 24, 2021.

Johnson & Johnson (NYSE: JNJ) has signed an agreement with the African Vaccine Acquisition Trust (AVAT) to supply up to 400 million doses of its single-shot COVID-19 vaccine to African Union member states. Initial deliveries are set for Q3 2021, pending regulatory approvals. The vaccine has shown a 67% reduction in symptomatic COVID-19 and is 85% effective at preventing severe disease. J&J's vaccine is designed for wide distribution, remaining stable at common refrigeration temperatures, enhancing its accessibility in remote areas.

Johnson & Johnson (NYSE: JNJ) announced that the World Health Organization (WHO) granted Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine. The vaccine shows a 67% reduction in symptomatic COVID-19 and 85% effectiveness against severe cases. This approval is pivotal for global vaccine distribution, particularly through the COVAX Facility, aiming to provide equitable access to lower-income countries. The vaccine's compatibility with standard storage and distribution makes it significant for pandemic response. Previous authorizations include Emergency Use Authorization in the U.S. and conditional approval in the EU.